Brain aging, Alzheimer's disease, and mitochondria

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 12, 2011, Pages 1630-1639

  Swerdlow, Russell H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid; Brain; Dementia; Mitochondria

Indexed keywords

AGING; ALZHEIMER DISEASE; BRAIN FUNCTION; BRAIN MITOCHONDRION; CLINICAL FEATURE; COGNITION; DEMENTIA; HUMAN; PRIORITY JOURNAL; REVIEW;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; HUMANS; MITOCHONDRIA;

EID: 80053892506     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.08.012     Document Type: Review

References (148)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
2. Association Alzheimer's Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7(2011):208-244.
3. Swerdlow R.H. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiol. Aging 2007, 28:1465-1480.
4. Amaducci L.A., Rocca W.A., Schoenberg B.S. Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosology. Neurology 1986, 36:1497-1499.
5. Boller F., Forbes M.M. History of dementia and dementia in history: an overview. J. Neurol. Sci. 1998, 158:125-133.
6. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989, 262:2551-2556.
7. Yaffe K., Middleton L.E., Lui L.Y., Spira A.P., Stone K., Racine C., Ensrud K.E., Kramer J.H. Mild cognitive impairment, dementia, and their subtypes in oldest old women. Arch. Neurol. 2011, 68:631-636.
8. Corrada M.M., Brookmeyer R., Berlau D., Paganini-Hill A., Kawas C.H. Prevalence of dementia after age 90: results from the 90+ study. Neurology 2008, 71:337-343.
9. Polvikoski T., Sulkava R., Rastas S., Sutela A., Niinisto L., Notkola I.L., Verkkoniemi A., Viramo P., Juva K., Haltia M. Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. Neuroepidemiology 2006, 26:76-82.
10. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., Ihara Y. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am. J. Pathol. 2000, 157:2093-2099.
11. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
12. Corrada M.M., Brookmeyer R., Paganini-Hill A., Berlau D., Kawas C.H. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann. Neurol. 2010, 67:114-121.
13. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
14. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
15. Hedden T., Gabrieli J.D. Insights into the ageing mind: a view from cognitive neuroscience. Nat. Rev. Neurosci. 2004, 5:87-96.
16. Borson S. Cognition, aging, and disabilities: conceptual issues. Phys. Med. Rehabil. Clin. N. Am. 2010, 21:375-382.
17. Folstein M., Folstein S. Functional expressions of the aging brain. Nutr. Rev. 2010, 68(Suppl 2):S70-S73.
18. Salthouse T.A. Memory aging from 18 to 80. Alzheimer Dis. Assoc. Disord. 2003, 17:162-167.
19. Crook T., Bahar H., Sudilovsky A. Age-associated memory impairment: diagnostic criteria and treatment strategies. Int. J. Neurol. 1987, 21-22:73-82.
20. Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int. Psychogeriatr. 1994, 6:63-68.
21. Richards M., Touchon J., Ledesert B., Richie K. Cognitive decline in ageing: are AAMI and AACD distinct entities?. Int. J. Geriatr. Psychiatry 1999, 14:534-540.
22. Goldman W.P., Morris J.C. Evidence that age-associated memory impairment is not a normal variant of aging. Alzheimer Dis. Assoc. Disord. 2001, 15:72-79.
23. Backman L., Jones S., Berger A.K., Laukka E.J., Small B.J. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 2005, 19:520-531.
24. Elias M.F., Beiser A., Wolf P.A., Au R., White R.F., D'Agostino R.B. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham cohort. Arch. Neurol. 2000, 57:808-813.
25. Jacobs D.M., Sano M., Dooneief G., Marder K., Bell K.L., Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology 1995, 45:957-962.
26. Masur D.M., Sliwinski M., Lipton R.B., Blau A.D., Crystal H.A. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994, 44:1427-1432.
27. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 2001, 58:397-405.
28. Sacuiu S., Sjogren M., Johansson B., Gustafson D., Skoog I. Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology 2005, 65:1894-1900.
29. Saxton J., Lopez O.L., Ratcliff G., Dulberg C., Fried L.P., Carlson M.C., Newman A.B., Kuller L. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8years prior to onset. Neurology 2004, 63:2341-2347.
30. Small B.J., Fratiglioni L., Viitanen M., Winblad B., Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch. Neurol. 2000, 57:839-844.
31. Tierney M.C., Yao C., Kiss A., McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10years. Neurology 2005, 64:1853-1859.
32. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
33. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 2001, 58:1985-1992.
34. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Backman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004, 256:240-246.
35. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
36. Enzinger C., Fazekas F., Ropele S., Schmidt R. Progression of cerebral white matter lesions - clinical and radiological considerations. J. Neurol. Sci. 2007, 257:5-10.
37. Resnick S.M., Pham D.L., Kraut M.A., Zonderman A.B., Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J. Neurosci. 2003, 23:3295-3301.
38. Haug H., Eggers R. Morphometry of the human cortex cerebri and corpus striatum during aging. Neurobiol. Aging 1991, 12:336-338. discussion 352-335.
39. Longstreth W.T., Manolio T.A., Arnold A., Burke G.L., Bryan N., Jungreis C.A., Enright P.L., O'Leary D., Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996, 27:1274-1282.
40. Anderton B.H. Ageing of the brain. Mech. Ageing Dev. 2002, 123:811-817.
41. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:67-77.
42. Rezek D.L., Morris J.C., Fulling K.H., Gado M.H. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 1987, 37:1365-1368.
43. Burns J.M., Church J.A., Johnson D.K., Xiong C., Marcus D., Fotenos A.F., Snyder A.Z., Morris J.C., Buckner R.L. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch. Neurol. 2005, 62:1870-1876.
44. Gouw A.A., Seewann A., Vrenken H., van der Flier W.M., Rozemuller J.M., Barkhof F., Scheltens P., Geurts J.J. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 2008, 131:3286-3298.
45. Scheltens P., Barkhof F., Leys D., Wolters E.C., Ravid R., Kamphorst W. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 1995, 45:883-888.
46. Scheltens P., Barkhof F., Valk J., Algra P.R., van der Hoop R.G., Nauta J., Wolters E.C. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain 1992, 115(Pt 3):735-748.
47. West M.J., Coleman P.D., Flood D.G., Troncoso J.C. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994, 344:769-772.
48. West M.J., Kawas C.H., Stewart W.F., Rudow G.L., Troncoso J.C. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol. Aging 2004, 25:1205-1212.
49. Imhof A., Kovari E., von Gunten A., Gold G., Rivara C.B., Herrmann F.R., Hof P.R., Bouras C., Giannakopoulos P. Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm?. J. Neurol. Sci. 2007, 257:72-79.
50. White L., Gelber R., Ross W., Masaki K., Uyehara-Lock J.H., Launer L., Petrovitch H. Dissonance in diagnoses of dementia type during life with attribution determined at autopsy in the Honolulu-Asia Aging Study; impact of high prevalence of mixed pathology and specificity/non-specificity of clinical manifestations in the very old. Neurology 2011, PL01.002.
51. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med. 2009, 360:2302-2309.
52. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
53. Hof P.R., Glannakopoulos P., Bouras C. The neuropathological changes associated with normal brain aging. Histol. Histopathol. 1996, 11:1075-1088.
54. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688.
55. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
56. Duyckaerts C., Hauw J.J. Prevalence, incidence and duration of Braak's stages in the general population: can we know?. Neurobiol. Aging 1997, 18:362-369. discussion 389-392.
57. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278. discussion 278-284.
58. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., McDonald W.C., Braak H., Petersen R.C. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 2003, 62:1087-1095.
59. Head E., Corrada M.M., Kahle-Wrobleski K., Kim R.C., Sarsoza F., Goodus M., Kawas C.H. Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol. Aging 2009, 30:1125-1134.
60. Davis D.G., Schmitt F.A., Wekstein D.R., Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 1999, 58:376-388.
61. Katzman R., Terry R., DeTeresa R., Brown T., Davies P., Fuld P., Renbing X., Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 1988, 23:138-144.
62. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001, 357:169-175.
63. Polvikoski T., Sulkava R., Myllykangas L., Notkola I.L., Niinisto L., Verkkoniemi A., Kainulainen K., Kontula K., Perez-Tur J., Hardy J., Haltia M. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 2001, 56:1690-1696.
64. Schmitt F.A., Davis D.G., Wekstein D.R., Smith C.D., Ashford J.W., Markesbery W.R. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000, 55:370-376.
65. Snowdon D.A. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 2003, 139:450-454.
66. Xuereb J.H., Brayne C., Dufouil C., Gertz H., Wischik C., Harrington C., Mukaetova-Ladinska E., McGee M.A., O'Sullivan A., O'Connor D., Paykel E.S., Huppert F.A. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann. N. Y. Acad. Sci. 2000, 903:490-496.
67. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
68. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
69. Phelps M.E., Barrio J.R. Correlation of brain amyloid with "aerobic glycolysis": a question of assumptions?. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17459-17460.
70. Nelson P.T., Abner E.L., Scheff S.W., Schmitt F.A., Kryscio R.J., Jicha G.A., Smith C.D., Patel E., Markesbery W.R. Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci. Lett. 2009, 450:336-339.
71. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
72. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
73. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
74. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009, 66:1469-1475.
75. Rentz D.M., Becker J.A., Moran E.K., Sardinha M., Manning L.N., S.T.M., Mathis C.M., DeKosky S.T., Klunk W.E., Sperling R.A., Fischman A.J., Johnson K.A. Amyloid imaging with Pittsburgh Compound-B (PIB) in AD, MCI, and highly intelligent older adults. Neurology 2006, 66:A66.
76. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
77. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
78. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
79. Delaere P., He Y., Fayet G., Duyckaerts C., Hauw J.J. Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol. Aging 1993, 14:191-194.
80. Berlau D.J., Corrada M.M., Head E., Kawas C.H. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 2009, 72:829-834.
81. Mizutani T., Shimada H. Neuropathological background of twenty-seven centenarian brains. J. Neurol. Sci. 1992, 108:168-177.
82. den Dunnen W.F., Brouwer W.H., Bijlard E., Kamphuis J., van Linschoten K., Eggens-Meijer E., Holstege G. No disease in the brain of a 115-year-old woman. Neurobiol. Aging 2008, 29:1127-1132.
83. Snowdon D.A., Kemper S.J., Mortimer J.A., Greiner L.H., Wekstein D.R., Markesbery W.R. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 1996, 275:528-532.
84. Smyth K.A., Fritsch T., Cook T.B., McClendon M.J., Santillan C.E., Friedland R.P. Worker functions and traits associated with occupations and the development of AD. Neurology 2004, 63:498-503.
85. Wilson R.S., Leurgans S.E., Boyle P.A., Bennett D.A. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch. Neurol. 2011, 68:351-356.
86. Amieva H., Le Goff M., Millet X., Orgogozo J.M., Peres K., Barberger-Gateau P., Jacqmin-Gadda H., Dartigues J.F. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann. Neurol. 2008, 64:492-498.
87. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
88. Lopez O.L., Jagust W.J., DeKosky S.T., Becker J.T., Fitzpatrick A., Dulberg C., Breitner J., Lyketsos C., Jones B., Kawas C., Carlson M., Kuller L.H. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch. Neurol. 2003, 60:1385-1389.
89. Jack C.R., Wiste H.J., Vemuri P., Weigand S.D., Senjem M.L., Zeng G., Bernstein M.A., Gunter J.L., Pankratz V.S., Aisen P.S., Weiner M.W., Petersen R.C., Shaw L.M., Trojanowski J.Q., Knopman D.S. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348.
90. Brys M., Pirraglia E., Rich K., Rolstad S., Mosconi L., Switalski R., Glodzik-Sobanska L., De Santi S., Zinkowski R., Mehta P., Pratico D., Saint Louis L.A., Wallin A., Blennow K., de Leon M.J. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging 2009, 30:682-690.
91. Buchhave P., Blennow K., Zetterberg H., Stomrud E., Londos E., Andreasen N., Minthon L., Hansson O. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 2009, 4:e6294.
92. Caroli A., Frisoni G.B. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's disease neuroimaging initiative cohort. Neurobiol. Aging 2010, 31:1263-1274.
93. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Rusinek H., Li J., Tsui W., Saint Louis L.A., Clark C.M., Tarshish C., Li Y., Lair L., Javier E., Rich K., Lesbre P., Mosconi L., Reisberg B., Sadowski M., DeBernadis J.F., Kerkman D.J., Hampel H., Wahlund L.O., Davies P. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 2006, 27:394-401.
94. Rami L., Fortea J., Bosch B., Sole-Padulles C., Llado A., Iranzo A., Sanchez-Valle R., Molinuevo J.L. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J. Alzheimers Dis. 2011, 23:319-326.
95. Gabuzda D., Busciglio J., Chen L.B., Matsudaira P., Yankner B.A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 1994, 269:13623-13628.
96. Gasparini L., Racchi M., Benussi L., Curti D., Binetti G., Bianchetti A., Trabucchi M., Govoni S. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci. Lett. 1997, 231:113-117.
97. Khan S.M., Cassarino D.S., Abramova N.N., Keeney P.M., Borland M.K., Trimmer P.A., Krebs C.T., Bennett J.C., Parks J.K., Swerdlow R.H., Parker W.D., Bennett J.P. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann. Neurol. 2000, 48:148-155.
98. Webster M.T., Pearce B.R., Bowen D.M., Francis P.T. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J. Neural Transm. 1998, 105:839-853.
99. Vlassenko A.G., Vaishnavi S.N., Couture L., Sacco D., Shannon B.J., Mach R.H., Morris J.C., Raichle M.E., Mintun M.A. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta ) deposition. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17763-17767.
100. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
101. Sahin E., Colla S., Liesa M., Moslehi J., Muller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., Maser R.S., Tonon G., Foerster F., Xiong R., Wang Y.A., Shukla S.A., Jaskelioff M., Martin E.S., Heffernan T.P., Protopopov A., Ivanova E., Mahoney J.E., Kost-Alimova M., Perry S.R., Bronson R., Liao R., Mulligan R., Shirihai O.S., Chin L., DePinho R.A. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
102. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
103. Gadaleta M.N., Cormio A., Pesce V., Lezza A.M., Cantatore P. Aging and mitochondria. Biochimie 1998, 80:863-870.
104. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 1992, 256:628-632.
105. Linnane A.W., Marzuki S., Ozawa T., Tanaka M. Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1989, 1:642-645.
106. Lenaz G., D'Aurelio M., Merlo Pich M., Genova M.L., Ventura B., Bovina C., Formiggini G., Parenti Castelli G. Mitochondrial bioenergetics in aging. Biochim. Biophys. Acta 2000, 1459:397-404.
107. Navarro A., Boveris A. The mitochondrial energy transduction system and the aging process. Am. J. Physiol. Cell Physiol. 2007, 292:C670-C686.
108. Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J.N., Rovio A.T., Bruder C.E., Bohlooly Y.M., Gidlof S., Oldfors A., Wibom R., Tornell J., Jacobs H.T., Larsson N.G. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
109. Kujoth G.C., Hiona A., Pugh T.D., Someya S., Panzer K., Wohlgemuth S.E., Hofer T., Seo A.Y., Sullivan R., Jobling W.A., Morrow J.D., Van Remmen H., Sedivy J.M., Yamasoba T., Tanokura M., Weindruch R., Leeuwenburgh C., Prolla T.A. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005, 309:481-484.
110. Lin M.T., Simon D.K., Ahn C.H., Kim L.M., Beal M.F. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum. Mol. Genet. 2002, 11:133-145.
111. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
112. Magistretti P.J., Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1155-1163.
113. Pellerin L., Magistretti P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10625-10629.
114. Pellerin L., Magistretti P.J. Food for thought: challenging the dogmas. J. Cereb. Blood Flow Metab. 2003, 23:1282-1286.
115. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., Beal M.F., Wallace D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet. 1992, 2:324-329.
116. Barrientos A., Casademont J., Cardellach F., Estivill X., Urbano-Marquez A., Nunes V. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res. Mol. Brain Res. 1997, 52:284-289.
117. Boveris A., Navarro A. Brain mitochondrial dysfunction in aging. IUBMB Life 2008, 60:308-314.
118. Minnick D.T., Pavlov Y.I., Kunkel T.A. The fidelity of the human leading and lagging strand DNA replication apparatus with 8-oxodeoxyguanosine triphosphate. Nucleic Acids Res. 1994, 22:5658-5664.
119. Ozawa T. Genetic and functional changes in mitochondria associated with aging. Physiol. Rev. 1997, 77:425-464.
120. Pavlov Y.I., Minnick D.T., Izuta S., Kunkel T.A. DNA replication fidelity with 8-oxodeoxyguanosine triphosphate. Biochemistry 1994, 33:4695-4701.
121. Mecocci P., MacGarvey U., Kaufman A.E., Koontz D., Shoffner J.M., Wallace D.C., Beal M.F. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 1993, 34:609-616.
122. Swerdlow R.H., Kish S.J. Mitochondria in Alzheimer's disease. Int. Rev. Neurobiol. 2002, 53:341-385.
123. Swerdlow R.H. Mitochondria and cell bioenergetics: increasinlgy recognized components and a possible etiologic cause of Alzheimer's disease, Antioxid. Redox Signal 2011, Sep 9. [Epub ahead of print].
124. Gibson G.E., Sheu K.F., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
125. Joffe G.T., Parks J.K., Parker W.D. Secondary inhibition of 2-ketoglutarate dehydrogenase complex by MPTP. Neuroreport 1998, 9:2781-2783.
126. Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., Wilson J.M., DiStefano L.M., Nobrega J.N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 1992, 59:776-779.
127. Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40:1302-1303.
128. Curti D., Rognoni F., Gasparini L., Cattaneo A., Paolillo M., Racchi M., Zani L., Bianchetti A., Trabucchi M., Bergamaschi S., Govoni S. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci. Lett. 1997, 236:13-16.
129. Parker W.D., Parks J.K. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 1995, 45:482-486.
130. Valla J., Schneider L., Niedzielko T., Coon K.D., Caselli R., Sabbagh M.N., Ahern G.L., Baxter L., Alexander G., Walker D.G., Reiman E.M. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006, 6:323-330.
131. Edland S.D., Silverman J.M., Peskind E.R., Tsuang D., Wijsman E., Morris J.C. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology 1996, 47:254-256.
132. L. Mosconi, M. de Leon, J. Murray, L. E, J. Lu, E. Javier, P. McHugh, R.H. Swerdlow, Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease, J. Alzheimers Dis. (2011) Aug 12 [Epub ahead of print].
133. Valla J., Yaari R., Wolf A.B., Kusne Y., Beach T.G., Roher A.E., Corneveaux J.J., Huentelman M.J., Caselli R.J., Reiman E.M. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 2010, 22:307-313.
134. Swerdlow R.H. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res. 2007, 85:3416-3428.
135. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10:279-288.
136. Vaishnavi S.N., Vlassenko A.G., Rundle M.M., Snyder A.Z., Mintun M.A., Raichle M.E. Regional aerobic glycolysis in the human brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17757-17762.
137. Brody D.L., Magnoni S., Schwetye K.E., Spinner M.L., Esparza T.J., Stocchetti N., Zipfel G.J., Holtzman D.M. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008, 321:1221-1224.
138. Baloyannis S.J. Mitochondrial alterations in Alzheimer's disease. J. Alzheimers Dis. 2006, 9:119-126.
139. de la Monte S.M., Luong T., Neely T.R., Robinson D., Wands J.R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab. Invest. 2000, 80:1323-1335.
140. Nagy Z., Esiri M.M., LeGris M., Matthews P.M. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol. 1999, 97:346-354.
141. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
142. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
143. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
144. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
145. Swerdlow R.H. Pathogenesis of Alzheimer's disease. Clin. Interv. Aging 2007, 2:347-359.
146. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20(Suppl 2):S265-S279.
147. Swerdlow R.H., Khan S.M. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 2004, 63:8-20.
148. Swerdlow R.H., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp. Neurol. 2009, 218:308-315.